98%
921
2 minutes
20
Purpose: To investigate the bacteriological characteristics of the gut microbiome in patients with prostate cancer and changes during and after radiation therapy.
Patients And Methods: Forty-one prostate cancer (PCa) patients treated with radiation therapy were included in the study. Fecal samples were collected at three points: before gold marker implantation into the prostate gland (K1), at the start (K2), and last day of radiotherapy (K3). Microbial identification was performed using MALDI-TOF MS, which allowed for precise identification at the species and genus levels. Blood biochemical parameters were assessed, and correlation analyses were performed.
Results: In total, 291 microbial isolates were identified, with the most common genera being (N=120), (N=31), and (N=30). A significant decrease in was observed in K3 compared with K1 and K2, whereas appeared exclusively at K2. Additionally, liver enzyme levels decreased, and IL-6 levels increased during treatment. These findings indicate significant shifts in the gut microbiota due to radiotherapy.
Conclusion: Radiation therapy alters the gut microbiota composition in patients with PCa, reduces microbial diversity, and promotes the growth of opportunistic pathogens. These changes are linked to biochemical parameters, suggesting a potential impact on health. Further research is needed to explore microbiome-targeted interventions during treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12405716 | PMC |
http://dx.doi.org/10.2147/CMAR.S517416 | DOI Listing |
BMC Urol
September 2025
Department of Radiology, Osaka Proton Therapy Clinic, 1-27-9 Kasugade naka, Osaka konohana-ku, Osaka, 554-0022, Japan.
Int Urol Nephrol
September 2025
Department of Urology, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St, ASB II-3, Boston, MA, 02115, USA.
Background: With the advancement of MR-based imaging, prostate cancer ablative therapies have seen increased interest to reduce complications of prostate cancer treatment. Although less invasive, they do carry procedural risks, including rectal injury. To date, the medicolegal aspects of ablative therapy remain underexplored.
View Article and Find Full Text PDFBr J Cancer
September 2025
Institute of Life Sciences, Bhubaneswar, Odisha, India.
Background: Docetaxel is the most common chemotherapy regimen for several neoplasms, including advanced OSCC (Oral Squamous Cell Carcinoma). Unfortunately, chemoresistance leads to relapse and adverse disease outcomes.
Methods: We performed CRISPR-based kinome screening to identify potential players of Docetaxel resistance.
Prostate Cancer Prostatic Dis
September 2025
Department of Urology, University of California Irvine, Irvine, CA, USA.
Eur Urol Focus
September 2025
Department of Urology, Medical Centre, University of Heidelberg, Heidelberg, Germany; Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany; Department of Urology, Philipps-University Marburg, Marburg, Germany.
Background And Objective: Since 2016, >21 000 patients with prostate cancer (PC) used our personalized online decision aid in routine care in Germany. We analyzed the effects of this online decision aid for men with nonmetastatic PC in a randomized controlled trial.
Methods: In the randomized controlled EvEnt-PCA trial, 116 centers performed 1:1 allocation of 1115 patients with nonmetastatic PC to use an online decision aid (intervention = I) or a printed brochure (control = C).